Oral Dosing
Dosing options to accommodate your patients1
Dosing options to accommodate your patients1
Patients previously treated with ≥2 TKIs:
There is also an option to take SCEMBLIX 40 mg tablets twice a day (AM + PM)
Recommended dosage for patients who have the T315I mutation is 200 mg bid AM + PM
Patients should:
Based on pharmacokinetic parameters studied in an exposure-response analysis, the predicted efficacy and safety profile of SCEMBLIX at the 80 mg once-daily dose is similar to that at the 40 mg bid dose.2
For the management of adverse reactions, reduce the SCEMBLIX dose as described in the table below.
ANC, absolute neutrophil count; PLT, platelets; ULN, upper limit of normal.
aBased on Common Terminology Criteria for Adverse Events (CTCAE) v4.03.
Myelosuppression
Thrombocytopenia, neutropenia, and anemia, including grade 3/4 reactions, have occurred in patients receiving SCEMBLIX
Perform complete blood counts every 2 weeks for the first 3 months of treatment and monthly thereafter or as clinically indicated. Monitor patients for signs and symptoms of myelosuppression...
SCEMBLIX is indicated for the treatment of adult patients with:
Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with 2 or more tyrosine kinase inhibitors (TKIs)
Ph+ CML in CP with the T315I mutation...